Variables | Cinnamon Group, n = 20 | Placebo Group, n = 19 | P** |
---|---|---|---|
Before Treatment | |||
hs-CRP (ng/ml) | 4392.80 ± 3969.60 | 6209.52 ± 4217.05 | 0.06 |
TNF-α (pg/ml) | 28.72 ± 35.52 | 17.12 ± 9.02 | 0.21 |
IL-6 (pg/ml) | 6.08 ± 2.40 | 6.33 ± 2.66 | 0.76 |
NF-kB (ng/ml) | 6.02 ± 15.74 | 1.96 ± 2.73 | 0.34 |
SIRT1 (ng/ml) | 5.54 ± 6.96 | 3.34 ± 0.29 | 0.13 |
After Treatment | |||
hs-CRP (ng/ml) | 3139.45 ± 2732.06 | 4155.42 ± 3422.95 | 0.29 |
Differences | - 1253.35 ± 2992.23 | - 2054.10 ± 3228.78 | 0.21 |
P* | 0.22 | 0.008 | |
TNF-α (pg/ml) | 28.88 ± 26.97 | 17.60 ± 8.56 | 0.27 |
Differences | - 1.84 ± 12.20 | 0.47 ± 8.60 | 0.81 |
P* | 0.90 | 0.84 | |
IL-6 (pg/ml) | 5.68 ± 1.33 | 6.09 ± 1.98 | 0.52 |
Differences | −0.40 ± 2.23 | - 0.23 ± 2.82 | 0.84 |
P* | 0.60 | 0.85 | |
NF-kB (ng/ml) | 3.48 ± 6.45 | 0.85 ± 0.58 | 0.02 |
Differences | - 2.53 ± 10.80 | - 1.11 ± 2.49 | 0.26 |
P* | 0.69 | 0.055 | |
SIRT1 (ng/ml) | 6.16 ± 12.13 | 3.62 ± 1.26 | 0.51 |
Differences | 0.62 ± 5.82 | 0.28 ± 1.27 | 0.23 |
P* | 0.39 | 0.38 |